SCHEMBL22609338

SCHEMBL22609338

CCOC(=O)c1c(N)c(C)nn1Cc1ccc(OC)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UCHL1 P09936 1/20 0.54
MAPK1 P28482 3/20 0.52
MAPT P10636 2/20 0.51
KDM4E B2RXH2 3/20 0.48
ALDH1A1 P00352 3/20 0.48
GAA P10253 3/20 0.48
HPGD P15428 2/20 0.48
GLA P06280 2/20 0.48
USP2 O75604 1/20 0.48
CASP1 P29466 1/20 0.48
CASP7 P55210 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
HSD17B10 Q99714 1/20 0.48
PDE4D Q08499 1/20 0.47
KMT2A Q03164 2/20 0.47
LMNA P02545 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
MEN1 O00255 1/20 0.47
NPC1 O15118 1/20 0.46
CYP1A2 P05177 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28894841 0.81 RAB9A (0.56) UCHL1MAPK1MAPTKDM4EALDH1A1
SCHEMBL3800033 0.81 UCHL1 (0.54) UCHL1MAPK1MAPTKDM4EALDH1A1
SCHEMBL9925007 0.81 MAPT (0.54) UCHL1MAPK1MAPTKDM4EALDH1A1
SCHEMBL22609303 0.81 PDE4D (0.53) UCHL1MAPK1MAPTKDM4EALDH1A1
SCHEMBL4221650 0.80 UCHL1 (0.56) UCHL1MAPK1MAPTKDM4EALDH1A1
SCHEMBL28443323 0.80 PKM (0.54) UCHL1MAPK1MAPTKDM4EALDH1A1
SCHEMBL5431338 0.79 MAPT (0.55) UCHL1MAPK1MAPTKDM4EALDH1A1
SCHEMBL25399382 0.78 L3MBTL1 (0.50) MAPK1MAPTKDM4EALDH1A1GAA
SCHEMBL23453706 0.77 UCHL1 (0.47) UCHL1MAPK1MAPTKDM4EALDH1A1
SCHEMBL16832321 0.77 GAA (0.69) MAPTKDM4EALDH1A1GAAUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115403584-B 2-thio-2, 3-dihydropyrimidine-4-one derivatives, pharmaceutical compositions, preparation methods and applications thereof 长春金赛药业有限责任公司 2024-04-02 CN disclosed
CN-111556871-B 1H-pyrazolo [4,3-b ] pyridines as PDE1 inhibitors H.隆德贝克有限公司 2023-07-07 CN disclosed
CN-111491936-B Macrocyclic compounds as PDE1 inhibitors H.隆德贝克有限公司 2023-07-04 CN disclosed
CN-115403584-A 2-thio-2, 3-dihydropyrimidine-4-one derivative, pharmaceutical composition, preparation method and application thereof 长春金赛药业有限责任公司 2022-11-29 CN disclosed
CN-111465410-B Combination therapy comprising administration of 1H-pyrazolo [4,3-B ] pyridine H.隆德贝克有限公司 2022-10-25 CN disclosed
CN-111526890-B Combination therapy comprising administration of 1H-pyrazolo [4,3-B ] pyridine H.隆德贝克有限公司 2022-10-14 CN disclosed
US-20210171503-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF ORFAN BIOTECH SL (ES) 2021-06-10 US disclosed
EP-3731840-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF Orfan Biotech Inc. (US) 2020-11-04 EP disclosed
CN-111556871-A 1H-pyrazolo [4,3-b ] pyridines as PDE1 inhibitors H.隆德贝克有限公司 2020-08-18 CN disclosed
CN-111526890-A Combination therapy comprising administration of 1H-pyrazolo [4,3-B ] pyridine H.隆德贝克有限公司 2020-08-11 CN disclosed
CN-111465410-A Combination therapy comprising administration of 1H-pyrazolo [4,3-B ] pyridine H.隆德贝克有限公司 2020-07-28 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210171503-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF PNPO, XDH, GLS UCHL1 1672/4885MAPK1 826/4885MAPT 2376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.